Neuren Pharmaceuticals in Australia sets primary goals for Phase III trial of NNZ-2591 drug in treating Phelan-McDermid syndrome (PMS) for 13 weeks, based on FDA meeting. Trial endpoints focus on communication and PMS symptoms improvement, following positive Phase II results.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing